Empagliflozin in Heart Failure Dialysis Patients

Not Applicable

Recruiting

• Conditions: Hemodialysis; Heart Failure
• Interventions: Drug: Empagliflozin10Mg Tab

• Registration Number: NCT05967156
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Empagliflozin is not still approved for glomerular filtration rate \< 20 cc/min/1.73m2. Considering the cardiac and renal benefits of this drug, the evaluation of the safety and efficacy of Empagliflozin for heart failure dialysis patients seems to be mandatory.

Detailed Description

Heart failure dialysis patients with residual renal function will be followed up on Empagliflozin based on echocardiographic parameters, pro-brain natriuretic peptide levels, diuresis volume, and serum acidity.

Study Timeline

• Study Start: 2023-06-01
• Study First Submitted: 2023-07-15
• Study First Submitted QC: 2023-07-21
• Study First Posted: 2023-08-01
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-29
• Last Update Posted: 2024-05-30
• Primary Completion: 2026-12-01
• Study Completion: 2027-03-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

• Heart failure on dialysis with residual renal function

Exclusion Criteria

• Dialysis patients with no residual urine

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Empagliflozin	Empagliflozin10Mg Tab	Heart failure dialysis patients will be treated with Empagliflozin

Primary Outcome Measures

Name	Time	Method
Brain Natriuretic Peptide	one month after administration	serum level

Trial Locations

Locations (1)

Nooshin Dalili; 🇮🇷 Tehran, Iran, Islamic Republic of